A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

By sjmartinez • July 3, 2025

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025 Jul 1;199:96-102. doi: 10.1016/j.ygyno.2025.06.014. Epub ahead of print. PMID: 40602355.

Tags: Bevacizumab, Hematology/Oncology, maintenance therapy, Niraparib, ovarian cancer, Publications

Related Posts

A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program

Bailey AV, Frochen S, Kwan L, Siavoshi M, Haroldsen CL, Shelton JB, Rose B, Maxwell KN, Nickols NG, Yamoah K, Rebbeck TR, Schoen MW, Rettig[...]

Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study

Ji J, Sun CL, Dale W, Cohen HJ, Kim H, Katheria V, Baclig N, Zektser Y, Niknafs A, Margolis S, Lee C, Smith C, Sedrak[...]

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ,[...]